The estimated Net Worth of Keyna Pidcock Skeffington is at least $1.96 million dollars as of 15 September 2022. Ms. Skeffington owns over 300 units of LivaNova PLC stock worth over $390,561 and over the last 7 years she sold LIVN stock worth over $0. In addition, she makes $1,567,930 as Senior Vice President et General Counsel and Company Secretary at LivaNova PLC.
Sign up
Ms. Skeffington LIVN stock SEC Form 4 insiders trading
Keyna has made over 16 trades of the LivaNova PLC stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 300 units of LIVN stock worth $14,235 on 15 September 2022.
The largest trade she's ever made was exercising 2,865 units of LivaNova PLC stock on 30 March 2022 worth over $135,944. On average, Keyna trades about 510 units every 47 days since 2018. As of 15 September 2022 she still owns at least 8,231 units of LivaNova PLC stock.
You can see the complete history of Ms. Skeffington stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Keyna Skeffington biography
Keyna Pidcock Skeffington J.D. serves as Senior Vice President, General Counsel and Company Secretary of the Company. Prior to joining the Company, Ms. Skeffington served in various roles at Medtronic Plc from 2004 to 2017, most recently as Vice President of Legal?–?Corporate and Securities and Assistant Secretary (2006 to 2017). She also served as Senior Legal Counsel for Medtronic’s Cardiac Surgery Business from 2005 to 2006. Before joining Medtronic, Ms. Skeffington was a Partner at the firm now known as Faegre Drinker Biddle & Reath LLP. Ms. Skeffington holds a BA in International Relations and Russian from Mount Holyoke College and a JD from Tulane University Law School
What is the salary of Keyna Skeffington?
As the Senior Vice President et General Counsel and Company Secretary of LivaNova PLC, the total compensation of Keyna Skeffington at LivaNova PLC is $1,567,930. There are 1 executives at LivaNova PLC getting paid more, with Damien McDonald having the highest compensation of $7,131,930.
How old is Keyna Skeffington?
Keyna Skeffington is 57, she's been the Senior Vice President et General Counsel and Company Secretary of LivaNova PLC since 2019. There are 11 older and 10 younger executives at LivaNova PLC. The oldest executive at LivaNova PLC is Arthur Rosenthal, 73, who is the Independent Director.
What's Keyna Skeffington's mailing address?
Keyna's mailing address filed with the SEC is 20 EASTBOURNE TERRACE, , LONDON, X0, W2 6LG.
Insiders trading at LivaNova PLC
Over the last 9 years, insiders at LivaNova PLC have traded over $79,802,010 worth of LivaNova PLC stock and bought 4,000 units worth $268,530 . The most active insiders traders include William A Kozy, Two S.C.A.Tower 6 S. A R.L.... et Peter M Wilver. On average, LivaNova PLC executives and independent directors trade stock every 10 days with the average trade being worth of $315,922. The most recent stock trade was executed by Peter M Wilver on 15 June 2024, trading 2,680 units of LIVN stock currently worth $127,166.
What does LivaNova PLC do?
livanova plc is a global medical technology company built on nearly five decades of experience and a relentless commitment to improve the lives of patients around the world. our advanced technologies and breakthrough treatments provide meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems.at livanova, we understand the importance of bringing both clinical and economic value to our customers. we are a strong, market-leading medical technology and services company, offering a diverse product portfolio and global reach. livanova is listed on the nasdaq stock exchange under the ticker symbol “livn.” livanova has approximately 3,000 employees worldwide. we are headquartered in london (uk) and maintain a presence in more than 100 countries. livanova is a worldwide leader in advanced circulatory support, cardiopulmonary and neuromodulation, dedicated to creating meaningful products and therapies that transform lives each and every day.
What does LivaNova PLC's logo look like?
Complete history of Ms. Skeffington stock trades at LivaNova PLC
LivaNova PLC executives and stock owners
LivaNova PLC executives and other stock owners filed with the SEC include:
-
Damien McDonald,
Chief Executive Officer, Director -
Keyna Skeffington,
Senior Vice President, General Counsel and Company Secretary -
Alistair Simpson,
Special Advisor -
Edward Andrle,
Special Advisor -
Damien McDonald,
CEO & Director -
Keyna Pidcock Skeffington,
Sr. VP, Gen. Counsel & Corp. Sec. -
Alex Shvartsburg,
CFO and Corp. VP of Financial Planning, Analysis & International Region -
Daniel Moore,
Independent Chairman of the Board -
Hugh Morrison,
Independent Director -
Alfred Novak,
Independent Director -
Francesco Bianchi,
Independent Director -
Arthur Rosenthal,
Independent Director -
Andrea Saia,
Independent Director -
Sharon O'Kane,
Independent Director -
William Kozy,
Independent Director -
Stacy Seng,
Independent Director -
Marco Dolci,
Head of Global Operations and R&D -
Roy Khoury,
President - International, Senior Vice President - Global Strategic Marketing -
Trui Hebbelinck,
Chief Human Resource Officer -
Alex Shvartsburg,
Interim Chief Financial Officer -
Stephanie Bolton,
Pres of International Region -
Paul R. Buckman,
Pres of Advanced Circulatory Support & GM of Transcatheter Mitral Valve Replacement -
Dr. Bryan D. Olin Ph.D.,
Sr. VP & Head of Product Devel. - Neuromodulation -
Trui Hebbelinck,
Chief HR Officer -
Matthew Joseph Dodds III,
Sr. VP of Corp. Devel. -
Deanna Wilke,
Director of Corp. Communications -
Lullo Stefano Di,
Pres Cardiac Rhythm Mgmt -
Michel Darnaud,
President Cardiac Surgery -
Thad Allen Huston,
Chief Financial Officer -
Vivid Sehgal,
CFO -
Two S.C.A.Tower 6 S. A R.L....,
-
Jacques Gutedel,
President Intercontinental -
Stefano Gianotti,
Director -
Piero Vecchi,
VP & Controller -
Pritpal Shinmar,
SR VP Global Market Access -
Robert Jason Richey,
President, Neuromodulation -
Douglas John Manko,
Chief Accounting Officer -
David S Wise,
SR VP HR & IT -
Todd C Schermerhorn,
Director -
Ahmet Tezel,
Chief Innovation Officer -
Brian Sheridan,
SR VP Genl Counsel & Secretary -
Andre Michel Ballester,
CEO -
Demetrio Mauro,
Chief Integration Officer -
James Christopher Barry,
Director -
Peter M Wilver,
Director -
Brooke Story,
Director -
Michael Damon Hutchinson,
Chief Legal Officer -
Stephanie Bolton,
President, Global Epilepsy -
Vladimir Makatsaria,
Chief Executive Officer